Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Advent France Biotechnology

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 24
Average round size
info
The average size of a deal this fund participated in
$16M
Portfolio companies 17
Lead investments 9
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.29
Key employees 5

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Life Science
  • Biopharma

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Advent France Biotechnology:
Typical Co-investors
Advent France Biotechnology is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Advent France Biotechnology:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Acronym Venture Capital Florida, Palm Beach, United States
Allrise Capital -
Anhui University of Technology Anhui, China, Maanshan
Beijing Boyu Cangqiong Keji Youxian Gongsi Beijing, Beijing, China
Crayhill Capital Management New York, New York, United States
Crowd Capital Ventures LLC Florida, Miami, United States
Enbei Investment -
ET Capital Partners California, Pleasanton, United States
Full Moon Investments Cary, North Carolina, United States
ICG Ventures La Vergne, Tennessee, United States
Keiretsu Capital Seattle, United States, Washington
KOSHIDAKA HOLDINGS Chiba Prefecture, Japan, Tateyama
Merstal Ltd. -
National Research Council of Canada Industrial Research Assistance Program Canada, Ontario, Ottawa
Newchip Austin, Texas, United States
Stellar Development Foundation California, San Francisco, United States
StreamS Capital, LLC Florida, Tampa, United States
TGVest Capital Taipei, Taiwan
Toho Holdings Japan, Tokyo

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Augustine Therapeutics

Biopharma
Biotechnology
Pharmaceutical
$20M26 Jun 2024 Ghent, East Flanders, Belgium

Orikine Bio

Biotechnology
Medical
Product Research
$6M18 Jul 2023 Barcelona, Catalonia, Spain

Astraveus

Biotechnology
$19M27 Jun 2023 Paris, Ile-de-France, France

Anoat Therapeutics

$2M19 Jun 2023 Paris, Ile-de-France, France

DiogenX

Biotechnology
Life Science
$39M10 May 2023 Marseille, Provence-Alpes-Côte d'Azur, France

ARTHEx Biotech

Biotechnology
$49M03 May 2023 Valencia, Valencian Community, Spain

Calida Therapeutics

Biotechnology
$2M06 Apr 2023 Paris, Ile-de-France, France

Integra Therapeutics

Biotechnology
Genetics
Health Care
$5M02 Dec 2021 Barcelona, Catalonia, Spain

Agalaia Therapeutics

Biotechnology
Health Care
Medical
Pharmaceutical
$4M27 Sep 2021 Paris, Ile-de-France, France
News
AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators

– AgomAb Therapeutics N.V. announced today the closing of a $74m Series B financing round led by Redmile Group, with participation from Cormorant Asset Management.
– All previous investors also participated in the round, including Advent France Biotechnology, Andera Partners, Boehringer Ingelheim Venture Fund, Omnes Capital, Pontifax, and V-Bio Ventures.
– The proceeds of the Series B will be used to fund clinical proof of concept of the lead program AGMB-101, an HGF-mimetic agonistic antibody, which is currently progressing through IND-enabling studies.
– The capital will also support further growth of the company’s pipeline of drug candidates designed to modulate regenerative pathways to induce functional organ recovery in acute and chronic diseases.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Advent France Biotechnology?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 24
Average round size 16M
Peak activity year 2019
Lead investments 9
Follow on index 0.29
Group Appearance index 0.83

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Augustine Therapeutics

Biopharma
Biotechnology
Pharmaceutical
$20M26 Jun 2024 Ghent, East Flanders, Belgium

Orikine Bio

Biotechnology
Medical
Product Research
$6M18 Jul 2023 Barcelona, Catalonia, Spain

Astraveus

Biotechnology
$19M27 Jun 2023 Paris, Ile-de-France, France

Anoat Therapeutics

$2M19 Jun 2023 Paris, Ile-de-France, France

DiogenX

Biotechnology
Life Science
$39M10 May 2023 Marseille, Provence-Alpes-Côte d'Azur, France

ARTHEx Biotech

Biotechnology
$49M03 May 2023 Valencia, Valencian Community, Spain

Calida Therapeutics

Biotechnology
$2M06 Apr 2023 Paris, Ile-de-France, France

Integra Therapeutics

Biotechnology
Genetics
Health Care
$5M02 Dec 2021 Barcelona, Catalonia, Spain

Agalaia Therapeutics

Biotechnology
Health Care
Medical
Pharmaceutical
$4M27 Sep 2021 Paris, Ile-de-France, France
Crunchbase icon

Content report

The following text will be sent to our editors: